ALYREF and malignant peripheral nerve sheath tumor: The vast majority of trials have focused on RAS effectors, such as the PI3K/AKT/mTOR or RAS/REF/MEK pathways, and unfortunately have failed to show clinical benefit, illustrating the need to identify other pathways as important targets for MPNST drug development.